KP1077 demonstrates clinically meaningful benefits for key IH symptoms Top-line data provide key information for the design of a Phase...
Mean muscle content-adjusted dystrophin expression of 9.0% and unadjusted dystrophin of 5.5%, with high consistency across participants, in a prespecified...
London, UK 24 September 2024 – George Medicines, a late-stage, biopharmaceutical company addressing significant unmet need in the treatment of...
Phase 1/2 clinical study will evaluate the safety and preliminary efficacy of KSQ-004EX in advanced solid tumorsLEXINGTON, Mass., Sept. 24,...
Seven presentations highlight the Company’s growing CNS portfolio and commitment to improving treatment outcomes for patients with sleep disordersNEW YORK,...
The agreement has been signed upon successful conclusion of a clinical study in dogs with osteoarthritis RAMAT GAN, Israel, Sept....
Multi-year agreement focuses on the manufacture of multiple CAR-Treg product candidates for Phase 1/2 clinical studies Partnership builds on long-term...
OXFORD, UK and CLEVELAND, Ohio, US, 24th September 2024 – The Oxford-Harrington Rare Disease Centre (‘OHC’), a partnership between the...
PARIS, Sept. 24, 2024 (GLOBE NEWSWIRE) -- AlgoTherapeutix (AlgoTx), a clinical stage biotechnology company developing a first-in-class therapeutic for peripheral...
— Approval based on results from global Phase III FRESCO-2 trial in patients with previously treated metastatic colorectal cancer — —...
Proceeds will be used to advance the Company’s IMANs into clinical trialsRaise underpins strong pre-clinical data demonstrating dual mechanism of...
BENTONVILLE, Ark., Sept. 23, 2024 /PRNewswire/ -- biophyle—a not-for-profit educational institution fostering collaboration between scientists and clinicians in Arkansas and...
Prior Phase 3 studies showed positive benefits in increasing unstimulated whole saliva secretionAinos aims to complete all regulatory approvals for...
New System Enhances Surgical Efficiency and Provides Versatile Solutions for Complex Spine ProceduresBELGRADE, MT / ACCESSWIRE / September 23, 2024...
– New data show istisociclib (KB-0742) triggered cell death in preclinical ovarian cancer models of platinum and PARP-inhibitor (PARPi) resistance –...
Press release OXFORD BIOMEDICA PLCINTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2024 Delivering Pure-Play CDMO Growth Strategy Continued...
FDA confirms that SciSparc’s study may proceed following the application submission a month ago TEL AVIV, Israel, Sept. 23, 2024...
The Phase 2b trial will enroll 5,000 subjects across clinical sites in the US and UKSAN DIEGO, Sept. 23, 2024...
Oral and poster presentations of results from Study 501 evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for...
FORT LEE, N.J., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd., today...